Prevalence of Human T- cell Lymphoma/Leukaemia Virus among Sudanese Blood Donors in Wad Medani, Sudan by Saliheen, Sara A et al.
 
 
EDITORIAL  
 
Gezira Journal Of Health Sciences 2016 vol.12(2) 
Gezira Journal Of Health Sciences 2016 vol.12(2) 
 
Prevalence of Human T- cell Lymphoma/Leukaemia Virus among 
Sudanese Blood Donors in Wad Medani, Sudan 
 
Sara A Saliheen1 , Awad Elseed Mustafa2, Sumia Elhag Mohammed3 
 
1. Department of Pathology ,Assistant professor,  National Cancer Institute, University of Gezira  
2. Professor of Pathology, Faculty of Medicine, U of G. 
3. Department of pathology, Medical labrotary, University of Gezira. 
Correspondence author: Sara Saliheen , email sarasaliheen@gmail.com 
  
Abstract: 
Background: HTLV type I/II is a blood borne infection that can be transmitted via blood transfusion.  
Objective: To determine the seroprevalence of human T – lymphotropic virus among blood donors in 
Wad Medani Central Blood Bank, Sudan. 
Methods: A total of 540 serum samples were collected from blood donors who visited the Wad Medani 
Central Blood Bank from January to July 2013. These sera were screened by ELISA for the 
determination of antibodies to T- Human Cell Lymphotropic Virus type 1/11.   
Results: Only one out of 540 (0.2%) samples was found to be positive for HTLV-I/II while 539 (96.4%) 
samples were negative.  
Conclusion: The seroprevalence of HTLV-I/II among the blood donors in Wad Medani Central Blood 
Bank was found to be very low, 0.20%. Therefore, there is no need for routine screening of blood donors 
for this virus. The introduction of these extra serological tests to the tests that already were carried out 
may have an extra financial burden, but because of the seriousness of the diseases that were caused by 
this virus, these tests should be carried out. 
 
Introduction: 
The Human T-lymphotropic virus is a human RNA (retrovirus). (1) Human T-cell lymphotropic 
virus type 1(HTLV-1), is also called the Adult T-cell lymphoma virus type1. HTLV-II, a virus 
closely related to HTLV-I, shares approximately 70% genomic homology (structural 
similarity) with HTLV/I. HTLV-III and HTLV-IV have been used to describe recently 
characterized viruses.(1)  HTLV is an enveloped, single-stranded RNA virus of the Retroviridae 
family, subfamily oncovirus. (2). HTLV-I/11 are transmitted mainly through transfusion of 
infected blood and cellular blood products, intravenous drug abuse, from mother to child 
including breast feeding and sexually (2)  .This virus has  relationship with two types of diseases, 
HTLV-associated myelopathy (HAM) or Tropical spastic paraparesis (TSP) and Adult T-cell 
Leukemia/Lymphoma (ATLL). ATLL according to the most recent World Health Organization 
(WHO) classification of lymphoid neoplasms is defined as a peripheral T-cell neoplasm 
associated with infection by the human T-lymphotropic virus type I (HTLV-I). Its incidence is 
(2-5%) (1). TSP and HAM are the same entities (3). It affects less than 2% of HTLV-I carriers 
(4).  
HTLV-I infects 15-20 million people worldwide, with endemic foci in southern Japan, the 
Caribbean, Melanesia, sub-Saharan Africa, Central and South America. The seroprevalence 
rate ranges from 3 to 6% in the Caribbean islands to about 27% in southern Japan. HTLV-II is 
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endemic in Amerindian tribes throughout North and South America and in Pygmy tribes in 
Central Africa, with seroprevalence ranging from 3 to 33%. The high risk of blood transfusion 
transmitted HTLV-I/II has prompted Japan, USA, several Caribbean countries, Canada, 
France, Holland, Denmark, Sweden, Portugal, Australia, and Greece to include screening for 
HTLV I/II in blood banks. Screening programme has been shown to reduce risk of transfusion 
related transmission in USA. There is a study that was made to determine the seroprevalence 
of HTLV1/2 among the blood donors in Osogbo, Nigeria in order to highlight the importance 
of including this in transfusion microbiology services in Nigeria. 14 (3.6%) samples were found 
to be positive for HTLV-I/II (5).Previous studies give the prevalence rates of HTLV antibody 
as 0.018%-0.043% in U.S, 0.01% in France, 3.0% in Japan, 1.5% in Trindad, 1.2% in Senegal 
and 0.022% in Saudi Arabia.(6). A study was conducted at Asvini, Mumbai, Five (1.9%) donors 
were found seropositive for HTLV-I/11(7). 
In Sudan several studies had been conducted for the prevelance of HBV and HIV among blood 
donors. (8, 9, 10) The prevelance of HTLV among Sudanese blood donors had not been studied 
before. 
The aim of this study is to determine the seroprevalence of HTLV among Sudanese blood 
donors attending wad Medani Central Blood Bank.  
Materials and Methods: 
Study setting: 
This study was conducted at Wad Medani Central Blood Bank, Gezira state, Sudan during 
January to July 2013. The Central Blood Bank provides blood to four governmental hospitals 
and other private hospitals in Wad Medani. About 1600 to 1700 donations are collected in Wad 
Medani central blood bank monthly.  
Inclusion criteria: 
Male blood donors attending Wad Medani Central Blood Bank, who were found suitable for 
donation, were included. 
Exclusion criteria: 
Subjects who came to donate and were found not suitable by Wad Medani Central Blood Bank 
criteria for suitable donors. 
Methods: 
Demographical data were collected from each study subject by using a questionnaire designed 
for this purpose.  
Five mls of venous blood were obtained under aseptic conditions in plain tubes.The serum was 
stored at 2-8°ᵒC till tested. These sera were screened using ELISA KITS HTLV1-11Ab third 
generation Enzyme immunoassay for the determination of antibodies to T- Cell Human 
Lymphotropic Virus type 1-11 in serum and plasma (DIA- PRO-Diagnostic Biprobes, Milano, 
Italy). 
Consent Ethical Clearance: 
Informing a verbal consent obtained from donors. 
Ethical Clearance was obtained from Faculty of Medicine, University of Gezira.  
  Results: 
During the study period 540 blood donors were recruited. The mean age was 28.72 ± 6.26 SD 
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with range between 20-60 years.The age distirbution is shown in figure1. Two hundred seventy 
nine (51.7%) of the donors from urban areas and 261(48.3%) from rural areas as shown in 
figure 2.  
The level of education of 384 (71.1%) was higher secondary school as shown in figure 3. Tribal 
background of the donors showed that 114 (21.1%) were Gaali, 99 (18.3%) were Kowahla in 
addition to other different tribes residing in Gezira area. 
Regarding the occupation, two hundred forty two (44.8%) of the donors were workers as shown 
in figure 4. Marital status was found to be two hundred ninty eight (55.2%) of them were single 
and 242 (44.8%) were married as shown in figure 5.   
Past history of hospitalization was reported by the study, seventy (13%) in (table1). The history 
of jaundice was not found in any one of the study subjects. Seventy (13%) had history of 
dentistry procedures table  
2. No one of them had a history of surgical operation or haemodialysis. 
Two hundred twenty one (40.9%) of the donors were found to be first time blood donors while 
319(59.1%) had repeated blood donation as in table3. Only one (0.20%) with history of blood 
transfusion as in table 4. 
Only one (0.20%) of the 540 blood donors was found to be positive for HTLVI-II as shown in 
figure 6, his age was 31 years old, from Elfow area. 
                                          
 
 
 
 
 
 
 
 
 
 
 
Figure (1): Age Group Distribution. N=540 
 
 
 
 
 
 
 
 
 
Figure (2): Donors Residence. N=540  
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Figure (3): Occupation of the donors. N=540 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (4): Education Level of the Donors. N=540 
 
 
Table (1): Past History of the Donors Hospitalization. N=540 
Donors Number Percent% 
Hospitalized 70 13% 
Not hospitalized 470 87.0% 
                          
Table (2): Past History of the Donors Dental Procedures. N=540 
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Donors Number Percent% 
dentistry procedure 70 13% 
No dentistry procedure 470 87.0% 
 
Table (3): Past History of the Donors Blood Transfusion, N=540 
Donors Number Percent% 
Transfused 1 0.2% 
Not transfused 539 99.8% 
 
Table (4): Frequency of Donation. N=540 
Donors Number Percent     % 
First time for blood donation              221                 40.9% 
Repeated donors              319                 59.1% 
 
 
Discussion: 
The approach to the selection of blood donors is to ensure the safety of the donor and to obtain 
a high quality of blood and blood component that is as safe as possible for the recipient. All 
donors were subjected to be screened for viral infections (hepatitis B, C, HIV and HTLVI/II) 
and the test for syphilis. Over 20 million persons are infected with HTLV-I/II globally. 
Continued identification of high risk groups is important for the control of the disease (11). 
In our subjects the only one positive case was detected by ELISA kits and confirmation by 
western blotting or PCR was not carried out.  No similar study was conducted in Sudan before 
to detect the prevalence of HTLV I-II.  
The low percentage of HTLVI-II in this study 0.20% in is agreement with study that was 
conducted in Saudi Arabia (0.022%) (6) and Senegal (0.16%) (5), but not in agreement with USA 
which reported 3-5% prevalence, or Japan where the HTLV-I/II has been shown to be endemic, 
with a prevalence of 27%. A study was carried out in the Caribbean countries where they found 
the prevalence to be 3-6%, Asvini, Mumbai, five (1.9%). Donors were found seropositive for 
HTLV-I/II and Central Africa ranges 3- 33%. Similar study that was made to determine the 
seroprevalence of HTLVI/II among  blood donors in Osogbo, Nigeria with prevalence rate 14 
(3.6%) samples were found to be positive for HLVI/II(5). The study which was carried out in 
Nigeria showed that the prevalence of HTLV-I/II infections was confined into two different 
age groups –between 18 and 24 (5.9%) and 25 and 31 (12.5%) with other different age groups 
showing zero prevalence,  the only one positive donor in that study was in age group 25-31 
years(5). 
In spite of the seropositivity of the positive donor for HTLVI-II and HBV in this study, there 
were other donors who were found to be positive for both HBV and HIV, but negative for 
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HTLVI-II, so there are no cross reactivity between these viruses.It is important to put in 
consideration the influx of expatriates from endemic areas for HTLVI-II into Sudan like 
Chinese, Koreans & Pakistanis, and the immigration from central and West Africa which are 
areas of high prevalence of this virus. 
                                     
Conclusion and Recommendations: 
The incidence of HTLVI-II among blood donors in this study is 0.20%. 
HTLV screening is now carried out in many parts of the world, and so it is recommended to 
repeat this study in several major blood banks in Sudan so as to be more repsentative.  
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